Treatment of pneumonias in a managed care organisation. The impact of a treatment guideline promotion on physician prescribing behaviour

Edward P Armstrong, P. C. Langley

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To evaluate a pneumonia disease management programme in a naturalistic setting. Design and Setting: A 300,000 member managed-care organisation introduced an antibacterial treatment guideline designed to change antibacterial prescribing by physicians. A relational database was created to measure changes in healthcare resources, use of antibacterials and health event profiles. One year of data before and after promoting the treatment guideline was compared. Intervention: The primary disease management intervention was the promotion of the guideline through mailings and face-to-face interventions by 2 disease management specialists. Participants: All patients with pneumonia diagnoses on the medical claims database were included in the analysis. Results: The study demonstrated that medical costs increased by 5 to 10% after the treatment guideline was implemented. Health event analysis demonstrated changes in antibacterial prescribing and average cost per antibacterial selected. In both years, the highest success rate was with the amoxicillin group. Although there were fewer patients, doxycycline also had success rates of at least 70%. The econometric model demonstrated that holding other variables constant, including patient age and the presence of any comorbidities, treatment with amoxicillin was associated with a statistically significant reduction in health event costs. Conclusions: The study identified the need for validating treatment guidelines with results from actual practice. The data also demonstrate the use and importance of measuring clinical and economic outcomes from disease management interventions by using databases readily available within most managed-care organisations. In addition, the econometric model was useful in comparing different drug groups with these retrospective data.

Original languageEnglish (US)
Pages (from-to)159-173
Number of pages15
JournalDisease Management and Health Outcomes
Volume6
Issue number3
DOIs
StatePublished - 1999

Fingerprint

Managed Care Programs
Pneumonia
Disease Management
Organizations
Guidelines
Physicians
Econometric Models
Amoxicillin
Databases
Therapeutics
Costs and Cost Analysis
Doxycycline
Health
Health Care Costs
Comorbidity
Economics
Delivery of Health Care
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Health Policy
  • Nursing(all)

Cite this

@article{c59f3d9f6e9f44e19135bf7c28927ef0,
title = "Treatment of pneumonias in a managed care organisation. The impact of a treatment guideline promotion on physician prescribing behaviour",
abstract = "Objective: To evaluate a pneumonia disease management programme in a naturalistic setting. Design and Setting: A 300,000 member managed-care organisation introduced an antibacterial treatment guideline designed to change antibacterial prescribing by physicians. A relational database was created to measure changes in healthcare resources, use of antibacterials and health event profiles. One year of data before and after promoting the treatment guideline was compared. Intervention: The primary disease management intervention was the promotion of the guideline through mailings and face-to-face interventions by 2 disease management specialists. Participants: All patients with pneumonia diagnoses on the medical claims database were included in the analysis. Results: The study demonstrated that medical costs increased by 5 to 10{\%} after the treatment guideline was implemented. Health event analysis demonstrated changes in antibacterial prescribing and average cost per antibacterial selected. In both years, the highest success rate was with the amoxicillin group. Although there were fewer patients, doxycycline also had success rates of at least 70{\%}. The econometric model demonstrated that holding other variables constant, including patient age and the presence of any comorbidities, treatment with amoxicillin was associated with a statistically significant reduction in health event costs. Conclusions: The study identified the need for validating treatment guidelines with results from actual practice. The data also demonstrate the use and importance of measuring clinical and economic outcomes from disease management interventions by using databases readily available within most managed-care organisations. In addition, the econometric model was useful in comparing different drug groups with these retrospective data.",
author = "Armstrong, {Edward P} and Langley, {P. C.}",
year = "1999",
doi = "10.2165/00115677-199906030-00005",
language = "English (US)",
volume = "6",
pages = "159--173",
journal = "Disease Management and Health Outcomes",
issn = "1173-8790",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Treatment of pneumonias in a managed care organisation. The impact of a treatment guideline promotion on physician prescribing behaviour

AU - Armstrong, Edward P

AU - Langley, P. C.

PY - 1999

Y1 - 1999

N2 - Objective: To evaluate a pneumonia disease management programme in a naturalistic setting. Design and Setting: A 300,000 member managed-care organisation introduced an antibacterial treatment guideline designed to change antibacterial prescribing by physicians. A relational database was created to measure changes in healthcare resources, use of antibacterials and health event profiles. One year of data before and after promoting the treatment guideline was compared. Intervention: The primary disease management intervention was the promotion of the guideline through mailings and face-to-face interventions by 2 disease management specialists. Participants: All patients with pneumonia diagnoses on the medical claims database were included in the analysis. Results: The study demonstrated that medical costs increased by 5 to 10% after the treatment guideline was implemented. Health event analysis demonstrated changes in antibacterial prescribing and average cost per antibacterial selected. In both years, the highest success rate was with the amoxicillin group. Although there were fewer patients, doxycycline also had success rates of at least 70%. The econometric model demonstrated that holding other variables constant, including patient age and the presence of any comorbidities, treatment with amoxicillin was associated with a statistically significant reduction in health event costs. Conclusions: The study identified the need for validating treatment guidelines with results from actual practice. The data also demonstrate the use and importance of measuring clinical and economic outcomes from disease management interventions by using databases readily available within most managed-care organisations. In addition, the econometric model was useful in comparing different drug groups with these retrospective data.

AB - Objective: To evaluate a pneumonia disease management programme in a naturalistic setting. Design and Setting: A 300,000 member managed-care organisation introduced an antibacterial treatment guideline designed to change antibacterial prescribing by physicians. A relational database was created to measure changes in healthcare resources, use of antibacterials and health event profiles. One year of data before and after promoting the treatment guideline was compared. Intervention: The primary disease management intervention was the promotion of the guideline through mailings and face-to-face interventions by 2 disease management specialists. Participants: All patients with pneumonia diagnoses on the medical claims database were included in the analysis. Results: The study demonstrated that medical costs increased by 5 to 10% after the treatment guideline was implemented. Health event analysis demonstrated changes in antibacterial prescribing and average cost per antibacterial selected. In both years, the highest success rate was with the amoxicillin group. Although there were fewer patients, doxycycline also had success rates of at least 70%. The econometric model demonstrated that holding other variables constant, including patient age and the presence of any comorbidities, treatment with amoxicillin was associated with a statistically significant reduction in health event costs. Conclusions: The study identified the need for validating treatment guidelines with results from actual practice. The data also demonstrate the use and importance of measuring clinical and economic outcomes from disease management interventions by using databases readily available within most managed-care organisations. In addition, the econometric model was useful in comparing different drug groups with these retrospective data.

UR - http://www.scopus.com/inward/record.url?scp=0032878224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032878224&partnerID=8YFLogxK

U2 - 10.2165/00115677-199906030-00005

DO - 10.2165/00115677-199906030-00005

M3 - Article

AN - SCOPUS:0032878224

VL - 6

SP - 159

EP - 173

JO - Disease Management and Health Outcomes

JF - Disease Management and Health Outcomes

SN - 1173-8790

IS - 3

ER -